RCM
RA Capital Management Portfolio holdings
AUM
$8.12B
1-Year Est. Return
46.06%
1 Year Est. Return
+46.06%
AUM
$5.94B
AUM Growth
-$52.2M
(-0.87%)
Holding
90
Top Buys
| 1 | +$111M | |
| 2 | +$29.3M | |
| 3 | +$27.4M | |
| 4 |
HNGE
Hinge Health
HNGE
|
+$15.5M |
| 5 |
Tyra Biosciences
TYRA
|
+$14.9M |
Top Sells
| 1 | +$58.6M | |
| 2 | +$46.8M | |
| 3 | +$45.6M | |
| 4 |
UroGen Pharma
URGN
|
+$35.5M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$33.1M |
Sector Composition
| 1 | Healthcare | 99.82% |
| 2 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Humacyte
HUMA
$242M
| – | – |
-3,312,356
|
|
||
77
IDEAYA Biosciences
IDYA
$3.01B
| – | – |
-1,347,252
|
|
||
78
Immatics
IMTX
$1.26B
| – | – |
-1,750,000
|
|
||
79
Lexeo Therapeutics
LXEO
$662M
| – | – |
-546,554
|
|
||
80
Nurix Therapeutics
NRIX
$1.73B
| – | – |
-1,333,333
|
|
||
81
Scilex Holding
SCLX
$124M
| – | – |
-29,606
|
|
||
82
Sera Prognostics
SERA
$127M
| – | – |
-3,032,808
|
|
||
83
Sutro Biopharma
STRO
$69.2M
| – | – |
-4,434,637
|
|
||
|
84
UroGen Pharma
URGN
$1.33B
| – | – |
-3,206,271
|
|
||
85
Xencor
XNCR
$1.19B
| – | – |
-575,000
|
|
||
86
Zai Lab
ZLAB
$2.21B
| – | – |
-1,295,040
|
|
||
87
Zura Bio
ZURA
$237M
| – | – |
-3,217,503
|
|
||
|
BOLD
88
Boundless Bio
BOLD
$25.1M
| – | – |
-2,180,631
|
|
||
|
BIOA
89
BioAge Labs
BIOA
$327M
| – | – |
-1,052,494
|
|
||
|
CBLL
90
CeriBell Inc
CBLL
$619M
| – | – |
-824,582
|
|